GlassScriptPhysician profile
Jaideep Shenoi
NPI 1821156233
$63,068.21
in general payments reported to CMS, 2019-2025
32 companies · $3,242 in 2025
The $3,242 reported for 2025 was more than what 75% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $14K · 2021: $14K · 2022: $8,276 · 2023: $3,326 · 2024: $2,430 · 2025: $3,242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,271 · Travel and Lodging: $423 · Food and Beverage: $279 · Education: $25.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,270.50 |
| Travel and Lodging | $423.24 |
| Food and Beverage | $278.74 |
| Education | $25.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $8,939.79 | 2019-2020 | |
| Incyte Corporation | $7,880.73 | 2019-2023 | |
| Janssen Biotech, INC. | $6,938.39 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $5,157.28 | 2019-2025 | |
| Pharmacosmos Therapeutics INC. | $4,948.05 | 2022 | |
| Global Blood Therapeutics, INC. | $4,527.40 | 2021 | |
| Exelixis INC. | $3,980.44 | 2019-2021 | |
| Eusa Pharma (US) LLC | $3,498.39 | 2021-2022 | |
| Astellas Pharma US INC | $2,923.33 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,635.36 | 2019-2020 | |
| Beigene USA, INC. | $2,275.00 | 2024 | Brukinsa |
| Abbvie INC. | $2,222.54 | 2019-2020 | |
| Deciphera Pharmaceuticals INC. | $2,150.00 | 2021 | |
| Glaxosmithkline, LLC. | $1,150.00 | 2020 | |
| Kite Pharma, INC. | $1,130.00 | 2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $857.82 | 2024-2025 | Pyrukynd |
| Jazz Pharmaceuticals INC. | $515.00 | 2019 | |
| Beigene, LTD. | $450.00 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $272.95 | 2019-2022 | |
| Lilly USA, LLC | $113.57 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $104.36 | 2019-2024 | Onivyde |
| Sanofi-Aventis U.S. LLC | $90.98 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $57.80 | 2019 | |
| Novartis Pharmaceuticals Corporation | $55.95 | 2019-2025 | |
| Genentech USA, INC. | $39.39 | 2019-2025 | Polivy |
| Pfizer INC. | $38.62 | 2019 | |
| Janssen Pharmaceuticals, INC | $25.72 | 2024 | |
| Puma Biotechnology, INC. | $22.58 | 2019 | |
| Myriad Genetic Laboratories, INC. | $21.74 | 2024 | Myrisk |
| Genzyme Corporation | $16.92 | 2019 | |
| Amgen INC. | $14.75 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaideep Shenoi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.